HomeCompareALID vs JNJ

ALID vs JNJ: Dividend Comparison 2026

ALID yields 400000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALID wins by $5.011119029548644e+32M in total portfolio value
10 years
ALID
ALID
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full ALID calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — ALID vs JNJ

📍 ALID pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALIDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALID + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALID pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALID
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, ALID beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALID + JNJ for your $10,000?

ALID: 50%JNJ: 50%
100% JNJ50/50100% ALID
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ALID
No analyst data
Altman Z
-48.1
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALID buys
0
JNJ buys
0
No recent congressional trades found for ALID or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALIDJNJ
Forward yield400000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$5.011119029548644e+32M$30.5K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$5.010957816668433e+32M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ALID vs JNJ ($10,000, DRIP)

YearALID PortfolioALID Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$40,010,700$40,000,000.00$10,594$274.49+$40.00MALID
2$149,615,521,729$149,572,710,280.37$11,294$360.69+$149615.51MALID
3$522,880,052,725,200$522,719,964,116,949.25$12,133$476.91+$522880052.71MALID
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$13,156$635.42+$1707862989289.03MALID
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$14,432$854.61+$5213509402845684.00MALID
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$16,056$1,162.76+$14874219058409543680.00MALID
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$18,175$1,604.53+$3.966119623405075e+22MALID
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$21,009$2,252.68+$9.88384363503273e+25MALID
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$24,911$3,229.73+$2.302052364743449e+29MALID
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$30,458$4,749.88+$5.011119029548644e+32MALID

ALID vs JNJ: Complete Analysis 2026

ALIDStock

Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States. It offers hemp-derived natural health products, including Liberty, a hemp-derived cannabidiol (CBD) tincture; Tactical Hydration, a CBD infused electrolyte replacement drink; FIZZ Tablets for adding in a water bottle; Battle Balm, a CBD roll on activity rub for aches and pains; and Quick Hit, a CBD gummy under the Tactical Relief brand. The company also provides Hydrosport CBD Drink, a CBD infused electrolyte replacement drink with sodium citrate electrolyte replacement; Hydrosport Tincture, a CBD tincture fortified with specific terpene profile; FIZZ Tablets for adding to a water bottle; Sport Rub, a CBD post-activity rub for aches and pains; and Quick Hit, a CBD gummy with vitamin B12 under the Equilibrium Bio brand. In addition, it offers Skin Structure, a facial formula topically applied to enhance skin's radiance and youthfulness; Eye Recover that helps the eye skin ward off free radicals, as well as helping to protect against sun damage; Glossy Lip Recover, which moisturizes and nourishes lips; Skin Designer that stimulates cell regeneration while minimizing age spots; Vitamin Absolute, a moisturizing facial oil; and Absolute Recover, a formulation that allows the infused bioactive compounds to be delivered directly to the desired areas of inflammation, pain, and other skin ailments under the MaXXa brand. In addition, it is developing ALID 10 and ALID 11, a pharma product, which is in Phase I clinical trial for treating post-traumatic stress disorder. The company was incorporated in 2013 and is headquartered in Kelowna, Canada.

Full ALID Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ALID vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALID vs SCHDALID vs JEPIALID vs OALID vs KOALID vs MAINALID vs ABBVALID vs MRKALID vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.